Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis

Cell Reports(2022)10.1016/j.celrep.2022.111384Source: DataRank Database

Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 1.1. It has been cited 41 times, with 37 citing works in its 1-hop citation network.

N/A

1.1DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access41 citations · 37 citing works in its network

Download PDF

Cite:

Linked data & code

geo nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02703714

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)Impact (FWCI 2.98)OA: goldTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 49%Citation Network 51%

Base Score Contribution

0.561

From this paper's citation signal

Citation Network Contribution

0.582

From 27 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 37 citers.

A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia
Signal Transduction and Targeted Therapy202410 citations51 referencesContributes 0.047
Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma
Cellular and Molecular Gastroenterology and Hepatology202415 citations64 referencesContributes 0.043
Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents
Liver Cancer202318 citations68 referencesContributes 0.043
Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer
Frontiers in Immunology20257 citations51 referencesContributes 0.041
Basal-to-inflammatory transition and tumor resistance via crosstalk with a pro-inflammatory stromal niche
Nature Communications202411 citations67 referencesContributes 0.037

Authors (19)

Elizabeth McCarthy ORCID,Arielle Ilano,Hai Yang ORCID,Li Zhang ORCID,Kathryn M. Allaire ORCID

Live enrichment

PubMed:36130508 PMC:PMC10060099 OpenAlex:https://openalex.org/W4296767449

National Institutes of Health

Grant: R21CA264381

National Institutes of Health

Grant: T32AI007334

NCI

Grant: R35CA253175

NCI

Grant: U01CA233100

NLM NIH HHS

Grant: R01 LM013763

NIAMS NIH HHS

Grant: P30 AR070155

National Institutes of Health

Grant: 5R35CA253175-03

Determinants of response to cancer immunotherapy

National Institutes of Health

Grant: 1U01CA233100-01

Molecular and immune drivers of immunotherapy responsiveness in prostate cancer

National Institutes of Health

Grant: 1R21CA264381-01

Computational approaches to unravel immune receptor sequencing for cancer immunotherapy

National Institutes of Health

Grant: 5T32AI007334-02

MOLECULAR AND CELLULAR IMMUNOLOGY

Bayer Fund

Parker Institute for Cancer Immunotherapy

Amgen

AstraZeneca

Bavarian Nordic

Cholangiocarcinoma Foundation

Gilead Sciences

Bristol-Myers Squibb

Conquer Cancer Foundation

Merck

Prostate Cancer Foundation

Relay Therapeutics

University of California, San Francisco

Genentech

AbbVie

Merck KGaA

FWCI

2.98

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.cell.com/article/S2211124722012190/pdf

publisherhttp://www.cell.com/article/S2211124722012190/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124722012190?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124722012190?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2022.111384

Fields of Study

Cancer Immunotherapy and BiomarkersImmune cells in cancerCholangiocarcinoma and Gallbladder Cancer Studies0301 basic medicine03 medical and health sciences0303 health sciencesHumansBiliary Tract NeoplasmsCytokinesEpitopesLeukocytes, MononuclearMonocytesParalysisT-Lymphocytes

MeSH Terms

EpitopesBiliary Tract NeoplasmsHumansLeukocytes, MononuclearMonocytesParalysisT-LymphocytesCytokines

Keywords

CD14ImmunotherapyMyeloidImmunologyCancer researchMedicinePeripheral blood mononuclear cellBiologyImmune systemMonocytesCholangiocarcinomaBiliary Tract CancerMyeloid CellsCheckpoint InhibitorsCp: CancerT-LymphocytesMononuclearMedical Physiology610ArticleEpitopesRare DiseasesClinical ResearchGeneticsLeukocytes2.1 Biological and endogenous factorsHumansParalysisCancerBiological SciencesGood Health and Well BeingBiliary Tract NeoplasmsLeukocytes, Mononuclearanti-PD-1CytokinesBiochemistry and Cell Biology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being